ClearPoint Neuro 2025 Q3 Earnings Misses Targets as Net Loss Widens 18.4%

ClearPoint Neuro (CLPT) reported fiscal 2025 Q3 earnings on Nov 7, 2025, with revenue rising 9.1% year-over-year to $8.86 million. , signaling confidence in its strategic initiatives.

Revenue

, while neurosurgery navigation and therapy revenue surged 20% to $3.4 million, driven by Prism Laser Therapy sales. , attributed to higher hardware and rental sales. , though product revenue dipped from delayed pharmaceutical trials.

Earnings/Net Income

ClearPoint’s losses deepened to $0.21 per share in Q3 2025, . , a 18.4% increase from $4.97 million in the prior year. The company has now reported losses for 11 consecutive years in the same quarter, underscoring persistent financial challenges.

Post-Earnings Price Action Review

The strategy of buying ClearPoint shares on revenue raise announcements and holding for 30 days yielded a 14.5% average return over three years, . This suggests historical success in capitalizing on positive momentum from earnings surprises, though recent stock performance has been volatile.

CEO Commentary

, including advancements in cell and gene therapy trials, the activation of the ClearPoint Advanced Laboratories facility, and a robotic neuro-navigation system. , . .

Guidance

. , .

Additional News

, . , . Additionally, the company appointed Dr. , .